ClinicalTrials.gg
WithdrawnNCT02056574ENACT-2Updated Aug 4, 2015

Safety and Efficacy Study of a Single Dose of NA-1 in Patients Undergoing Endovascular Repair of Ruptured Aneurysms

A Phase 2 interventional study of NA-1 and Placebo in Subarachnoid Hemorrhage and Ruptured Intracranial Aneurysm, sponsored by NoNO Inc.. Withdrawn at 12 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-04.

Sponsored by NoNO Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Subarachnoid Hemorrhage with a site in Canada — 4 open to participants now, 5 under way, none of them phase 3. Subarachnoid Hemorrhage · Canada.

Enrollment
22nd of 23
0 · median 73
Started
2015
with 1 other
Phase 2
4 of 27
none open now
Registered
13th of 27
by date

Among the 27 studies in Subarachnoid Hemorrhage with a site in Canada, this one is the 22nd largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2015, is one of 4 in phase 2, and was the 13th registered.

Subarachnoid Hemorrhage

513 studies on the registry are indexed under Subarachnoid Hemorrhage; 131 are open to participants now.

Browse Subarachnoid Hemorrhage studies →

Open to participants now

4 of the 27 studies in Subarachnoid Hemorrhage with a site in Canada are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 92 Subarachnoid Hemorrhage studies recruiting now, 58 (63%) set no upper age limit and 5 (5%) stop at 75 or younger; 8 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Subarachnoid Hemorrhage with a site in Canada, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, single-dose study investigating the safety and efficacy of NA-1 in patients with subarachnoid hemorrhage (SAH) undergoing endovascular repair of ruptured intracranial aneurysms. Up to 300 male and female patients with SAH undergoing endovascular repair of a ruptured intracranial aneurysm will be dosed with 2.60 mg/kg of NA-1 or placebo as a 10 minute intravenous infusion after completion of the endovascular procedure on Day 1 of the study period. Subjects will undergo interim procedures at Day 2-4, Day 30-45, and end-of-study procedures on Day 90.

03

Conditions studied

  • Subarachnoid Hemorrhage
  • Ruptured Intracranial Aneurysm

Keywords

  • Endovascular repair
  • Subarachnoid hemorrhage
  • Ruptured intracranial aneurysm
  • Stroke
  • Coiling
  • NA-1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. A diagnosis of a ruptured brain aneurysm deemed suitable for repair by neuroendovascular techniques involving intraluminal occlusion by detachable platinum coils, or any neuroendovascular technique such as balloon-assisted coiling, stenting, or flowed diversion.
    1. Patient should be Grade II-IV on the WFNS grading scale for SAH.
    1. Male or female with a minimum age of 18 years on the day of enrolment.
    1. Female subjects of : Negative pregnancy test.
    1. Non-surgically sterile males or males with partners of childbearing potential must be willing to use condoms with spermicide for 3 months after completion of dosing.
    1. Body weight less than or equal to 180 kg.
    1. Vital signs on admission:

      • Blood pressure between 80-180 mm Hg systolic/50-100 mm Hg diastolic;
      • Body temperature ≤ 38.5C.
    1. and availability of the subject for the entire study period and willingness of the subject to adhere to protocol requirements.

Exclusion criteria

Exclusion Criteria:

    1. Prior SAH within 6 months of presentation.
    1. Dissecting or mycotic brain aneurysm.
    1. Planned endovascular vessel sacrifice as the primary modality for aneurysm treatment.
    1. Known history of life-threatening allergic reaction to any medication.
    1. Chronic renal disease defined as a baseline serum creatinine > 150 µmol/L.
    1. Women who are pregnant, or have a positive urine or blood (β-hCG) pregnancy test.
    1. Women who are breastfeeding.
    1. Any psychiatric or psychological disease, which would preclude the patient from completing the protocol.
    1. Pre-morbid (estimated) modified Rankin scale score of >1.
    1. Previous major stroke.
    1. Patients with known infection.
    1. Participation in a clinical trial with an drug within 30 days preceding this study.
    1. Previous participation in the ENACT trial (e.g, to treat a prior aneurysm), participation in another trial involving NA-1 or prior receipt of NA-1.
    1. Any other medical condition that the site investigator deems would put the patient at excessive risk of participation in the study or an expected less than 1 year or that would result in inability to collect clinical outcomes at 90 days.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    NA-1

    20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and an 11 amino acid domain that enables the peptide to cross the blood-brain barrier. Single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion.

    Drug: NA-1

  • Placebo comparator
    Placebo

    Single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Modified Rankin Scale (mRS)

    Proportion of subjects achieving independent functioning as defined as a score of 0-1 on the mRS at Day 90.

    Time frame: 90 days

Secondary outcomes

  1. Modified Rankin Scale (mRS)

    Proportion of subjects achieving a good outcome as defined as a score of 0-1 on the mRS at Day 30-45.

    Time frame: 30-45 days

  2. National Institutes of Health Stroke Scale (NIHSS)

    Proportion of subjects achieving a good outcome as defined as a score of 0-1 on the NIHSS at Day 90.

    Time frame: 90 days

  3. Mortality

    Rate of subarachnoid hemorrhage related mortality over the 90 day study period.

    Time frame: 90 days

  4. In-hospital length of stay

    Duration of in-hospital length of stay.

    Time frame: 90 days

07

Study locations

12 sites
  • Barrow Neurological Institute
    Phoenix, Arizona 850139, United States
  • Colorado Neurological Institute
    Englewood, Colorado 801130000, United States
  • University of Michigan - Neurosurgery
    Ann Arbor, Michigan 481090000, United States
  • Oregon Health and Science University
    Portland, Oregon 97239-3098, United States
  • University of Wisconsin
    Madison, Wisconsin 537920000, United States
  • Foothills Medical Centre
    Calgary, Alberta T2N 2T9, Canada
  • QEII Health Sciences Centre - Halifax Infirmary
    Halifax, Nova Scotia B3H 3A7, Canada
  • London Health Sciences Centre
    London, Ontario N6A 5A5, Canada
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
  • St. Michael's Hospital
    Toronto, Ontario M5B 1W8, Canada
  • Toronto Western Hospital
    Toronto, Ontario M5T 2S8, Canada
  • Hopital de l'Enfant Jesus
    Quebec City, Quebec G1J 1Z4, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2015, a primary completion of Nov 2019 and a completion of Apr 2020. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2014
First posted
Feb 6, 2014
Start
Nov 2015
Primary completionEst.
Nov 2019
CompletionEst.
Apr 2020
Last update
Aug 4, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02056574
Lead sponsor
NoNO Inc.
Responsible party
Sponsor
First posted
Feb 6, 2014
Start date
Nov 2015
Primary completion
Nov 2019 (estimated)
Completion
Apr 2020 (estimated)
Last update
Aug 4, 2015

Study contacts

Michael Tymianski, MD, PhD
study director · NoNO Inc.
Cameron G McDougall, MD
principal investigator · Barrow Neurological Institute
Michael D Hill, MD
principal investigator · Foothills Medical Centre

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nerinetide

Start the discussion